View Post

Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race

In Clinical Trials by Barbara Jacoby

News provided by: WCG/Genomic Health From: prnewswire.com Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple Oncotype DX Breast Recurrence Score® (RS) presentations at the 2018 San Antonio Breast Cancer Symposium® (SABCS), reinforcing the value of the Oncotype DX® test in optimizing treatment and outcomes in patients with both node-negative and node-positive early-stage breast cancer. Among the data presented …

View Post

New clinical trials at Roswell Park build on virus research for innovative immunotherapy approach

In Clinical Trials by Barbara Jacoby

By: Katie Alexander From: www.wivb.com The Roswell Park Comprehensive Cancer Center is once again on the cutting-edge of research to find new cures, and Western New Yorkers could play a big role as clinical trials open for an innovative new approach to immunotherapy. Over the decades, there has been a lot of progress for certain types of cancers with immunotherapies, …

View Post

Combatting The Professional Patient Problem In Clinical Trials

In Clinical Trials by Barbara Jacoby

By: John Carlos Diaz, GeoSera Consulting From: clinicalleader.com Clinical research patients are compensated for their participation in clinical trials. The compensation is based on the burden the trial imposes on the patient and is vetted through an institutional review board, so patients are not overly influenced by financial gain to enroll. Unfortunately, in some therapeutic areas and types of clinical …

View Post

Todos Medical Presents Encouraging Scientific Abstract

In Clinical Trials by Barbara Jacoby

Source: Todos Medical Ltd. From: apnews.com Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, presented its scientific abstract discussing the most recent clinical trial results of the TM-B1 cancer screen test at the 2018 San Antonio Breast Cancer Symposium (SABCS) earlier today. The TM-B1 cancer …

View Post

Amgen Contributes to Nonprofit to Support Greater Diversity in Clinical Trials

In Clinical Trials by Barbara Jacoby

By: Alex Keown From: biospace.com Amgen provided $2 million to the nonprofit Lazarex Cancer Foundation to support an effort to improve minority patient access to the potentially life-saving drugs in oncology clinical trials. Amgen’s contribution will go to Lazarex’s IMPACT (IMproving Patient Access to Cancer Clinical Trials) program, which is focused on improving patient enrollment, retention, minority participation and equitable …

View Post

CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer

In Clinical Trials by Barbara Jacoby

From: globenewswire.com CytoDyn Inc. (OTCQB:CYDY), a biotechnology company developing  a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, including metastatic cancers, human immunodeficiency virus (HIV) and graft-versus-host disease (GvHD) is pleased to announce that on November 23, 2018, it received FDA approval of its IND submission and is allowed to initiate a phase 1b/2 clinical trial for metastatic triple-negative breast …

View Post

Novartis reports new positive data from MONALEESA trials

In Clinical Trials by Barbara Jacoby

From: drugdevelopment-technology.com Novartis has reported positive results from three pivotal Phase III MONALEESA trials evaluating kisqali (ribociclib) plus endocrine therapy in combination with endocrine therapy alone for the treatment of human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in patients with difficult-to-treat visceral disease. The results are based on subgroup analyses and demonstrated that kisqali plus endocrine therapy …

View Post

Generon Presented Positive Phase III Results From a Double-Blind, Placebo Controlled-Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy

In Clinical Trials by Barbara Jacoby

From: apnews.com Dec 8, 2018–Generon BioMed Holding Ltd. (Generon), announced today at the annual San Antonio Breast Cancer Symposium (SABCS), positive results from a placebo-controlled trial with F-627, a recombinant human Granulocyte Colony Stimulating Factor (rhG-CSF) protein, designed using Generon’s Dikine TM technology platform. Led by Principle Investigator Dr. John Glaspy, Estelle, Abe and Marjorie Endowed Chair in Cancer Research …

View Post

Olaparib Extends PFS in Ovarian Cancer in SOLO-1 Clinical Trial

In Clinical Trials by Barbara Jacoby

By: Sarah Tilyou From: clinicaloncology.com Maintenance therapy with olaparib can reduce the risk for ovarian cancer progression and related death by 70% at three years, according to results of the phase 3 SOLO-1 trial.  The findings, which were presented at the ESMO 2018 Congress (abstract LBA7_PR) and published in The New England Journal of Medicine (2018 Oct 21. [Epub ahead …